Posted by Michael Wonder on 28 May 2020
Cardiff Oncology announces fast track designation granted by the FDA to onvansertib for second-line treatment of KRAS mutated colorectal cancer
28 May 2020 - Fast Track designation for onvansertib in KRAS mutated metastatic colorectal cancer underscores the urgent need for new treatment options for these patients.
Cardiff Oncology today announced that the U.S. FDA granted fast track designation to onvansertib, its oral and highly-selective Polo-like kinase 1 inhibitor, for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.
